Ivo Klepáček

Ivo Klepáček

Auto-generated profile, based on publicly available information

Ivo Klepáček

Department of Anatomy, First Faculty of Medicine, Charles University, Praha

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2008 in Journal of Biomechanics
Verified
Journal Article
Closed access
PŠPetr Šidlof
Petr Šidlof
JŠJan G. Švec
Jan G. Švec
JHJaromír Horáček
Jaromír Horáček
JVJan Veselý
Jan Veselý
IKIvo Klepáček
Ivo Klepáček
RHRadan Havlík
Radan Havlík

1 January 2016 in Biocybernetics and Biomedical Engineering
Verified
Journal Article
Closed access
TVTomáš Vampola
Tomáš Vampola
JHJaromír Horáček
Jaromír Horáček
IKIvo Klepáček
Ivo Klepáček

1 February 2006 in Nutritional Neuroscience
Verified
Journal Article
Closed access
WRWaleed M. Renno
Waleed M. Renno
FSFarid Saleh
Farid Saleh
IKIvo Klepacek
Ivo Klepacek
GAGhanim Al-Khaledi
Ghanim Al-Khaledi
HIHussam Ismael
Hussam Ismael
SASami Asfar
Sami Asfar
We investigated the effect of green tea (GT) in unilateral chronic constriction injury (CCI) to the rat scaitic nerve. Five groups ( n = 6 rats/group) sham group: rats which underwent operation but with no ligation to the scaitic nerve, and received tap water for two weeks before and for five weeks after the surgery. Four experimental groups underwent CCI to the right sciatic nerve, divided randomly as follows: group E were given tap water throughout the study. Group B received GT before and after CCI. Group C was given GT following CCI. Group D received GT for two weeks prior to CCI. Groups which consumed GT showed significant improvement in the toe spread ( P Consumption of GT improves both reflexes and sensation which are often affected in the course of peripheral neuropathy.

1 October 2005 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FSF Saleh
F Saleh
WRWaleed M. Renno
Waleed M. Renno
IKI Klepacek
I Klepacek
GIG Ibrahim
G Ibrahim
HDH Dashti
H Dashti
CKCrotty Kerry
Crotty Kerry
To develop an effective pharmaceutical treatment for a disease, we need to fully understand the biological behavior of that disease, especially when dealing with cancer. The current available treatment for cancer may help in lessening the burden of the disease or, on certain occasions, in increasing the survival of the patient. However, a total eradication of cancer remains the researchers hope. Some of the discoveries in the field of medicine relied on observations of natural events. Among these events is the spontaneous regression of cancer. It has been argued that such regression could be immunologically-mediated, but no direct evidence has been shown to support such an argument. We, hereby, provide compelling evidence that spontaneous cancer regression in humans is immunologically-mediated, hoping that the results from this study would stimulate the pharmaceutical industry to focus more on cancer vaccine immunotherapy. Our results showed that patients with ≥3 primary melanomas (very rare group among cancer patients) develop significant histopathological spontaneous regression of further melanomas that they could acquire during their life (P = 0.0080) as compared to patients with single primary melanoma where the phenomenon of spontaneous regression is absent or minimal. It seems that such regression resulted from the repeated exposure to the tumor which mimics a selfimmunization process. Analysis of the regressing tumors revealed heavy infiltration by T lymphocytes as compared to non-regressing tumors (P < 0.0001), the predominant of which were T cytotoxic rather than T helper. Mature dendritic cells were also found in significant number (P < 0.0001) in the regressing tumors as compared to the non regressing ones, which demonstrate an active involvement of the different arms of the immune system in the multiple primary melanoma patients in the process of tumor regression. Also, MHC expression was significantly higher in the regressing versus the non-regressing tumors (P < 0.0001), which reflects a proper tumor antigen expression. Associated with tumor regression was also loss of the melanoma common tumor antigen Melan A/ MART-1 in the multiple primary melanoma patients as compared to the single primary ones (P = 0.0041). Furthermore, loss of Melan A/ MART-1 in the regressing tumors significantly correlated with the presence of Melan A/ MART-1-specific CTLs in the peripheral blood of these patients (P = 0.03), which adds to the evidence that the phenomenon of regression seen in these patients was immunologicallymediated and tumor-specific. Such correlation was also seen in another rare group of melanoma patients, namely those with occult primary melanoma. The lesson that we could learn from nature in this study is that inducing cancer regression using the different arms of the immune system is possible. Also, developing a novel cancer vaccine is not out of reach.

1 October 2005 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FSF. Saleh
F. Saleh
WRWaleed M. Renno
Waleed M. Renno
IKI. Klepacek
I. Klepacek
GIG. Ibrahim
G. Ibrahim
SAS. Asfar
S. Asfar
ABA. Behbehani
A. Behbehani
Abstract: The incidence of cancer and its related morbidity and mortality remain on the increase in both developing and developed countries. Cancer remains a huge burden on the health and social welfare sectors worldwide and its prevention and cure remain two golden goals that science strives to achieve. Among the treatment options for cancer that have emerged in the past 100 years, cancer vaccine immunotherapy seems to present a promising and relatively safer approach as compared to chemotherapy and radiotherapy. The identification of different tumour antigens in the last fifteen years using a variety of techniques, together with the molecular cloning of cytotoxic T lymphocytes (CTLs)- and tumour infiltrating lymphocytes (TILs)-defined tumour antigens allowed more refining of the cancer vaccines that are currently used in different clinical trials. In a proportion of treated patients, some of these vaccines have resulted in partial or complete tumour regression, while they have increased the disease-free survival rate in others. These outcomes are more evident now in patients suffering from melanoma. This review provides an update on melanoma vaccine immunotherapy. Different cancer antigens are reviewed with a detailed description of the melanoma antigens discovered so far. The review also summarises clinical trials and individual clinical cases in which some of the old and current methods to vaccinate against or treat melanoma were used. These include vaccines made of autologous or allogenic melanoma tumour cells, melanoma peptides, recombinant bacterial or viral vectors, or dendritic cells.

25 November 2002 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
Petr JežekPetr Ježek
Petr Ježek
MNMilos Nekvasil
Milos Nekvasil
EŠEva Škobisová
Eva Škobisová
EUEva Urbánková
Eva Urbánková
MJMilan Jirsa
Milan Jirsa
IKIvo Klepáček
Ivo Klepáček